Daniel D. Von Hoff, M.D., F.A.C.P., chief scientific officer for both US Oncology Research and Scottsdale Healthcares Clinical Research Institute in Phoenix, AZ, agrees that 50,000 patients participating in clinical trials is an impressive number. He also believes the careful and innovative care that is given to each individual is even more impressive. According to Von Hoff, "It is an extraordinary accomplishment to bring these breakthrough therapies to over 50,000 patients and help bring 43 new drugs to patients fighting cancer everywhere – but its not just about the number. Its the care and hope that each patient receives that counts."
Patricia Noel, a 67-year old patient at New York Oncology Hematology in Troy, NY is one of the patients benefiting from a trial offered through US Oncology Research. Noel, who was diagnosed with Metastatic Breast Cancer (MBC) in 2008, has been enrolled for approximately 10 months in a Phase II study of a novel therapy in patients previously treated for MBC. She knew early in her battle of the disease that she would seek trial opportunities.
"My mother participated in a clinical trial, and my son is an AIDS researcher," Noel explains. "I began participating in a trial not as a last resort, but because I am in this fight not only for myself and my family, but to help researchers learn more about this disease and help others who will battle it in the future."
Dr. Nicholas Vogelzang, medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and chair and medical director of the developmental therapeutics committee and co-chair of the genitourinary committee for US Oncology Research points out that patients from all walks of life participate in and benefit from ground breaking clinical trials offered by US Oncology Research. "We can now document that over 50,000 patients have been touched by these life changing trials," Vogelzang claims. "And that doesnt even count all the other patients and future patients touched by the knowledge weve gained."
"I learned early in my career that patients come first, everything else second," says Kevin Coker, vice president of US Oncology Research, McKesson Specialty Health. "The people who work with US Oncology Research have that same philosophy, which has led to great advancements in the way cancer is treated and more hope for patients and their families."
US Oncology Research is one of the strongest and most reputable community research networks in the world. Collectively, its patients, physicians, and research professionals have contributed greatly to advancing the science of cancer care and improved patient outcomes.
About US Oncology Research
McKesson Specialty Health conducts clinical trials through US Oncology Research, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.
About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.
Posted by Sean Fenske, Editor-in-Chief, MDT